Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on June 6, 2025
Sleep Apnea Devices Market worth US$9.3 billion by 2029 | MarketsandMarkets™.
GlobeNewswire
·
June 6, 2025
Delray Beach, FL, June 06, 2025 (GLOBE NEWSWIRE) -- The global sleep apnea devices market valued at US$6.0 billion in 2023, stood at US$6.5 billion in 2024 and is projected to advance at a resilient CAGR of 7.3% from 2024 to 2029, culminating in a …
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
GlobeNewswire
·
June 6, 2025
NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
GlobeNewswire
·
June 6, 2025
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said …
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the …
Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
GlobeNewswire
·
June 6, 2025
Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with favorable safety Demonstrated greater α-synuclein reductions compared to other gene therapy approaches LONDON, June …
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
GlobeNewswire
·
June 6, 2025
New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or minimal itch with ZORYVE cream 0.15% or ZORYVE cream 0. …
PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing
GlobeNewswire
·
June 6, 2025
Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership …
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June …
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 6, 2025
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, …
Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million
GlobeNewswire
·
June 6, 2025
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG …
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
GlobeNewswire
·
June 6, 2025
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 …
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
GlobeNewswire
·
June 6, 2025
RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the …
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
GlobeNewswire
·
June 6, 2025
UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its Clinical Science Advisory Board to …
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression
GlobeNewswire
·
June 6, 2025
- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment-resistant depression (TRD) - SAN …
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
GlobeNewswire
·
June 6, 2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
GlobeNewswire
·
June 6, 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 …
Polpharma Group soutient l’action urgente de l’UE visant à garantir l’accès aux médicaments et à renforcer la souveraineté pharmaceutique européenne
GlobeNewswire
·
June 6, 2025
AMSTERDAM, 06 juin 2025 (GLOBE NEWSWIRE) -- Polpharma Group, fabricant européen de produits pharmaceutiques de premier plan, s’est joint aux autres membres de l’association Medicines for Europe pour signer une lettre ouverte adressée aux Premiers ministres …
Die Polpharma Group unterstützt dringende Maßnahmen der EU zur Sicherung des Zugangs zu Arzneimitteln und zur Stärkung der pharmazeutischen Souveränität Europas
GlobeNewswire
·
June 6, 2025
AMSTERDAM, June 06, 2025 (GLOBE NEWSWIRE) -- Die Polpharma Group, ein führender europäischer Pharmahersteller, hat sich anderen Mitgliedern von Medicines for Europe angeschlossen und einen offenen Brief an die Premierminister und Gesundheitsminister aller …
Burning Rock Reports First Quarter 2025 Financial Results
GlobeNewswire
·
June 6, 2025
GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today …
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
GlobeNewswire
·
June 6, 2025
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. …